AYA.AX Artrya Limited ASX A$2.70 (Market Closed 24 Mar 2026): AI stock outlook

Artrya Limited (AYA.AX) closed at A$2.70 on the ASX on 24 Mar 2026, a small rise from the prior close. The AYA.AX stock has moved from a 52-week low of A$0.56 to a 52-week high of A$5.24, highlighting wide swings in market sentiment. Trading volume was 608,820 shares versus an average of 524,780, keeping liquidity adequate for ASX mid-caps. This piece examines the AYA.AX stock fundamentals, technicals, Meyka AI grade and near-term price forecasts for investors focused on AI healthcare plays.

AYA.AX stock: Price action and market snapshot

AYA.AX stock traded between A$2.69 and A$2.88 today and closed at A$2.70. Market cap stands at A$298,156,000.00 with 113,800,000.00 shares outstanding. Volume of 608,820.00 was slightly above the 50-day average of 524,780.00, showing modest renewed interest. Year-to-date performance is down 48.32%, while the 1-year return is up 235.90%, underlining high volatility in the stock.

AYA.AX stock: Fundamentals and valuation

Artrya operates AI software for coronary CT analysis, listed on ASX in 2021. Trailing EPS is -0.17, producing a negative PE of -15.41. Book value per share is 0.71 and price-to-book is 3.69, roughly in line with healthcare information peers. Cash per share of 0.61 supports runway. Revenue per share is minimal at 0.00, reflecting early commercial scale. High R&D spend at 84.34% of revenue signals product investment rather than near-term profits.

AYA.AX stock: Technicals and trading levels

Technically, AYA.AX stock shows oversold momentum. RSI is 34.28, MACD is negative and the CCI reads -183.06, suggesting short-term weakness. Bollinger Bands sit at Upper A$3.58, Middle A$3.12, Lower A$2.66, so current price is near the lower band and support around A$2.66. Short-term resistance is near A$3.12 and stronger resistance near A$3.58. Average true range is 0.24, indicating intraday moves around that level.

AYA.AX stock: Meyka AI grade and model forecast

Meyka AI rates AYA.AX with a score out of 100: 63 (B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects Monthly A$3.05, Quarterly A$4.36 and 12‑month A$7.41. Relative to the current price A$2.70, the model implies near-term upside of 12.96% to monthly and 61.48% to the quarterly forecast. Forecasts are model-based projections and not guarantees.

AYA.AX stock: Risks and opportunities

Opportunity: Artrya’s Salix AI targets a large coronary CT market and R&D focus supports product differentiation. A successful sales ramp could convert heavy R&D into scalable revenue. Risk: negative margins are material. Net income per share is -0.16 and operating cash flow per share is -0.17, so further capital needs or dilution remain possible. Regulatory adoption and hospital buying cycles add execution risk for the AYA.AX stock.

AYA.AX stock: Sector comparison and market context

In the Healthcare sector on ASX, average PE is 26.57 and average PB is 3.97. AYA.AX stock’s PB of 3.69 sits near sector norms but the company’s negative earnings separate it from profitable peers like CSL and ResMed. Sector 3-month performance is down 11.47%, which has pressured medtech and healthcare information stocks. Investors should view AYA.AX as an AI healthcare growth play, not a yield or value stock.

Final Thoughts

Key takeaways for the AYA.AX stock: Artrya closed at A$2.70 on 24 Mar 2026 with solid intraday liquidity and high volatility. Fundamentals show heavy R&D spending, negative EPS -0.17, and strong cash per share 0.61, which supports near-term operations but delays profitability. Technically the stock is oversold with RSI 34.28 and trading near the lower Bollinger band A$2.66, offering tactical entry levels for risk-tolerant investors. Meyka AI’s forecast model projects A$7.41 in 12 months, implying an upside of 174.36% versus the current price. Shorter targets include A$3.05 (monthly) and A$4.36 (quarter), implying 12.96% and 61.48% upside respectively. These are model outputs and not guarantees. Investors should balance the growth opportunity in AI cardiac diagnostics against execution and funding risks. For more data see Artrya’s site and ASX filings and check the Artrya (AYA.AX) page on Meyka AI for live updates. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.